Drug Profile
Research programme: HMG CoA reductase inhibitor/caffeine (StatC) - Canopus BioPharma
Alternative Names: Aerosolised statins for influenza - Canopus BioPharma; Influenza statin antivirals - Canopus BioPharma; Influenza therapies - Canopus BioPharma; StatC; Statin/Caffeine aerosolised for influenza - Canopus BioPharmaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Canopus BioPharma
- Class
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype; Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in China (Intranasal, Aerosol)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA (Intranasal, Aerosol)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in China (Intranasal, Aerosol)